Autoimmune Diseases Statistical and Clinical Coordinating Center (AD-SCCC)

The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), announces a forecasted funding opportunity for the establishment of the Autoimmune Diseases Statistical and Clinical Coordinating Center (AD-SCCC). This initiative is designed to support ongoing and future clinical trials in autoimmune diseases, mucosal immunology, and primary immune deficiencies. The AD-SCCC will serve as a vital component in orchestrating statistical analysis, regulatory compliance, clinical monitoring, repository oversight, manuscript preparation, and study archiving for NIH-funded trials. It will also work closely with the Division of Allergy, Immunology, and Transplantation's Clinical Data and Safety Management Center (CDSMC) and may extend its services to other clinical research networks within NIAID’s scope. The purpose of this funding opportunity is to enhance the efficiency and scientific rigor of clinical studies by providing a centralized infrastructure for biostatistical and clinical coordination. The selected institution will be expected to deliver expertise in study development, monitor both domestic and international regulatory frameworks, and support data sharing and publication efforts. The role of the AD-SCCC is central to improving the operational and analytical aspects of NIAID’s autoimmune disease research agenda, with flexibility for emergent support of other NIH trials as needed. The funding instrument type is a cooperative agreement, indicating significant involvement by NIH staff in project oversight and execution. The total program funding is estimated at $8,000,000, with one award expected. The forecasted opportunity does not require matching funds. Specific allowable costs or restrictions are not detailed in the forecast, but all expenditures are expected to align with federal regulations governing clinical research support. Eligible applicants include a wide range of organizations, such as state and local governments, independent school districts, tribal entities (both federally recognized and other Native American organizations), nonprofit and for-profit organizations (including small businesses), public and private institutions of higher education, public housing authorities, and regional and community-based organizations. This broad eligibility scope reflects NIAID’s intention to attract institutions with demonstrated capacity in coordinating complex, multi-site clinical research. Applications are estimated to open on March 6, 2026, with a due date of June 4, 2026. Awards are anticipated by March 1, 2027, which will also mark the project start date. The opportunity is classified as recurring, implying that it may be reissued on a regular basis. It was last updated and forecasted on December 4, 2025. Interested applicants are encouraged to contact Jeffrey Rice, Ph.D., at jeffrey.rice@nih.gov or 240-627-3552 for additional information. This opportunity is being made available under the authority of Sections 301 and 405 of the Public Health Service Act (42 USC 241 and 284), as amended, and pursuant to federal regulations at 42 CFR Part 52 and 2 CFR Part 200. Full application instructions and forms will be made available via Grants.gov when the opportunity transitions from forecast to active.